Document is current

Article History

Received: 28 May 2024

Accepted: 19 July 2024

First Online: 18 September 2024

Declarations

:

: Malaz Boustani and Louis P. Garrison report fees from Eli Lilly and Company during conduct of this study. Erin G. Doty, Mark Belger, Andrew W. Spargo, and Joseph A. Johnston are employees and minor shareholders of Eli Lilly and Company. Lee J. Smolen, Timothy M. Klein, and Daniel R. Murphy are employees of Medical Decision Modeling Inc., which received compensation from Eli Lilly for the research that contributed to this article. The authors have indicated that they have no other conflicts of interest regarding the content of this article.

: TRAILBLAZER-ALZ 2 was conducted according to the Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice Guideline, and local regulatory requirements []. An independent ethics committee/institutional review board at each site approved the study protocol. Participants and study partners provided written consent []. An independent data and safety monitoring board provided trial oversight []. The present study is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.